首页> BMC cancer> Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.

导出 OA

翻译打印收藏纠错

第一作者： Wei,Wu

第一单位： Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, China.

作者： Wei,Wu ^[1] ; Jiewen,Chen ^[1] ; Heran,Deng ^[1] ; Liang,Jin ^[1] ; Zhanghai,He ^[2] ; Nanyan,Rao ^[1] ; Yan,Nie ^[1] ; Yandan,Yao ^[1] ; Yaping,Yang ^[1] ; Fengxi,Su ^[1] ; Jieqiong,Liu ^[3]

作者单位： Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, China. ^[1] Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. ^[2] Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, China. liujieqiong01@163.com. ^[3]

关键词 ER-positive and HER2-negative breast cancer Epirubicin and cyclophosphamide (FEC)Everolimus plus letrozole Fluorouracil Randomized neoadjuvant pilot trial